The estimated Net Worth of Thomas K Equels is at least 1.77 百万$ dollars as of 6 May 2024. Mr Equels owns over 61,729 units of AIM ImmunoTech Inc stock worth over 241,159$ and over the last 16 years he sold AIM stock worth over 0$. In addition, he makes 1,524,108$ as Exec. Vice Chairman、 CEO & Pres at AIM ImmunoTech Inc.
Mr has made over 38 trades of the AIM ImmunoTech Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 61,729 units of AIM stock worth 25,309$ on 6 May 2024.
The largest trade he's ever made was buying 200,000 units of AIM ImmunoTech Inc stock on 11 April 2017 worth over 100,000$. On average, Mr trades about 23,440 units every 37 days since 2009. As of 6 May 2024 he still owns at least 778,184 units of AIM ImmunoTech Inc stock.
You can see the complete history of Mr Equels stock trades at the bottom of the page.
Thomas K. Equels Esq., J.D., M.S. is the Exec. Vice Chairman, CEO & Pres at AIM ImmunoTech Inc.
As the Exec. Vice Chairman、 CEO & Pres of AIM ImmunoTech Inc, the total compensation of Mr S at AIM ImmunoTech Inc is 1,524,108$. There are 1 executives at AIM ImmunoTech Inc getting paid more, with William Mitchell having the highest compensation of 1,696,680$.
Mr S is 68, he's been the Exec. Vice Chairman、 CEO & Pres of AIM ImmunoTech Inc since . There are 6 older and 8 younger executives at AIM ImmunoTech Inc. The oldest executive at AIM ImmunoTech Inc is William Mitchell, 81, who is the Chairman of the Board.
Thomas's mailing address filed with the SEC is 2117 SOUTHWEST HIGHWAY 484, , OCALA,, FL, 34473.
Over the last 20 years, insiders at AIM ImmunoTech Inc have traded over 15,026,013$ worth of AIM ImmunoTech Inc stock and bought 898,126 units worth 656,210$ . The most active insiders traders include Thomas K Equels、J Mervyn Nabors、Commercial Bank First. On average, AIM ImmunoTech Inc executives and independent directors trade stock every 125 days with the average trade being worth of 16,943$. The most recent stock trade was executed by Thomas K Equels on 6 May 2024, trading 61,729 units of AIM stock currently worth 25,309$.
aim immunotech inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the united states. the company's products include alferon n injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. it is also developing ampligen for the treatment of hepatitis b and hiv, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. aim immunotech inc. has research agreement with the japanese national institute of infectious diseases and shionogi & co., ltd. to test its drug ampligen as an adjuvant therapy for covid-19, the new coronavirus infectious disease caused by sars-cov-2. the company was formerly known as
AIM ImmunoTech Inc executives and other stock owners filed with the SEC include: